

Question for written answer E-004953/2025

to the Commission

Rule 144

Paolo Inselvini (ECR), Carlo Fidanza (ECR)

Subject: EU procurement for stocks of antigens, vaccines and diagnostic reagents against animal lumpy skin disease (LSD)

Lumpy Skin Disease is classified as an animal disease (mainly bovine) of Group A in accordance with Delegated Regulation (EU) 2018/1629¹ supplementing Regulation (EU) 2016/429². This classification requires immediate eradication/control measures to be taken by Member States and allows the Commission to establish EU stocks of antigens-vaccines and diagnostic reagents.

Articles 48 to 49 of Regulation (EU) 2016/429 empower the Commission to establish, manage, renew and make available EU stocks for listed diseases. Implementing Regulation (EU) 2022/140³ also regulates the associated operational measures: supply, replacement, management and distribution.

The epidemiological evolution of LSD in the Member States, including Italy, highlights the importance of ensuring timely availability of vaccines/diagnostic materials, including with regard to the EU stock replacement/renewal needs provided for in the legislation.

In view of the above:

1. Can the Commission say when it intends to launch and publish a new EU tender procedure for the procurement of antigens, vaccines and diagnostic reagents against LSD, under Articles 48 to 49 of Regulation (EU) 2016/429?
2. What transitional measures are currently available/actionable to provide support to Member States should this be required at a time when EU stocks need to be replaced/renewed/supplemented?
3. How is the Commission ensuring that the epidemiological evolution of LSD is being adequately taken into account in the planning, scaling and renewal of EU stocks for that disease?

Submitted: 15.12.2025

¹ https://eur-lex.europa.eu/eli/reg_del/2018/1629/oj/eng.

² <https://eur-lex.europa.eu/eli/reg/2016/429/oj/eng>.

³ https://eur-lex.europa.eu/eli/reg_impl/2022/140/oj/eng.